The American College of Rheumatology (ACR) most recently published recommendations
for the use of diseasemodifying antirheumatic drugs (DMARDs) and biologic agents in the …

Background 12 months of oral cyclophosphamide has been shown to alter the progression
of scleroderma-related interstitial lung disease when compared with placebo. However, …

Systemic sclerosis, also known as scleroderma, is a rare and complex autoimmune
connective-tissue disease. Once considered an untreatable and unpredictable condition, research …

Background Systemic sclerosis (SSc) is a rare, complex, connective tissue disorder. Interstitial
lung disease (ILD) is common in SSc, occurring in 35–52% of patients and accounting for …

Systemic sclerosis (SSc) is a systemic autoimmune disease affecting multiple organ systems,
including the lungs. Interstitial lung disease (ILD) is the leading cause of death in SSc. …

Objective To assess survival and identify predictors of survival in patients with systemic
sclerosis-interstitial lung disease (SSc-ILD) who participated in the Scleroderma Lung Studies (…

Objective To compare mycophenolate mofetil (MMF) with placebo for the treatment of systemic
sclerosis (SSc)–related interstitial lung disease (ILD). Methods We included participants …

Systemic sclerosis (SSc) has the highest cause-specific mortality of all the connective tissue
diseases, and the aetiology of this complex and heterogeneous condition remains an …

Rationale: FVC percent predicted (FVC%) is the primary outcome measure in clinical trials
of systemic sclerosis interstitial lung disease. For interpretation of change in the FVC% over …

Objective To compare colonic microbial composition in systemic sclerosis (SSc) patients
and healthy controls and to determine whether certain microbial genera are associated with …